Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor.
about
Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunctionIn cardiomyocytes, binding of unzipping peptide activates ryanodine receptor 2 and reciprocally inhibits calmodulin bindingPatient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular TachycardiaAntiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC ModelsDynamic, inter-subunit interactions between the N-terminal and central mutation regions of cardiac ryanodine receptorCatecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.Arrhythmic effects of Epac-mediated ryanodine receptor activation in Langendorff-perfused murine hearts are associated with reduced conduction velocity.Intracellular translocation of calmodulin and Ca2+/calmodulin-dependent protein kinase II during the development of hypertrophy in neonatal cardiomyocytes.Pharmacokinetic evaluation of oral dantrolene in the dog.Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapyDantrolene suppresses spontaneous Ca2+ release without altering excitation-contraction coupling in cardiomyocytes of aged mice.Computational analysis of calcium signaling and membrane electrophysiology in cerebellar Purkinje neurons associated with ataxia.FRET-based trilateration of probes bound within functional ryanodine receptors.The ryanodine receptor in cardiac physiology and disease.Dissociation of calmodulin from cardiac ryanodine receptor causes aberrant Ca(2+) release in heart failure.Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor.Disruption of calcium homeostasis in cardiomyocytes underlies cardiac structural and functional changes in severe sepsis.A low-dose β1-blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the sarcoplasmic reticulumEffects of dantrolene on arrhythmogenicity in isolated regional ischemia-reperfusion rabbit hearts with or without pacing-induced heart failure.Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia.Essential Role of Calmodulin in RyR Inhibition by Dantrolene.Dantrolene prevents arrhythmogenic Ca2+ release in heart failureOxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity.Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.Recombinant Atrial Natriuretic Peptide Prevents Aberrant Ca2+ Leakage through the Ryanodine Receptor by Suppressing Mitochondrial Reactive Oxygen Species Production Induced by Isoproterenol in Failing Cardiomyocytes.Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias.Enhanced binding of calmodulin to the ryanodine receptor corrects contractile dysfunction in failing hearts.Ryanodine receptor mutations in arrhythmia: The continuing mystery of channel dysfunction.Targeting ryanodine receptors for anti-arrhythmic therapy.Novel molecular targets for atrial fibrillation therapy.Themes and variations in ER/SR calcium release channels: structure and function.New directions in antiarrhythmic drug therapy for atrial fibrillation.Electrical storm: recent pathophysiological insights and therapeutic consequences.Ryanodine receptors: physiological function and deregulation in Alzheimer disease.Structural and functional interactions within ryanodine receptor.The emerging role of calmodulin regulation of RyR2 in controlling heart rhythm, the progression of heart failure and the antiarrhythmic action of dantrolene.Emerging pathways driving early synaptic pathology in Alzheimer's disease.Murine Electrophysiological Models of Cardiac Arrhythmogenesis.Dantrolene improves in vitro structural changes induced by serum from Trypanosoma cruzi-infected mice.
P2860
Q24302344-C996FF98-200B-4488-9761-F9FA9C4F855AQ24305644-72CBAB6C-E1B0-469F-A550-797BBD19B588Q28067569-C85831DD-CED1-4C20-90B2-38D7275BF9ECQ28547114-3FC95796-B0E0-444D-A46A-EB7B5D89136DQ28589538-82D55AF8-FDCB-4670-9440-D041DBF6A807Q30494293-2E1986C2-CA4E-447E-8FB8-EEE1EE0B6385Q30557177-E620AAA9-2A06-4D3D-A756-1CC39C636963Q33845927-2F2D0277-5F91-4B60-908B-1A67975E2359Q33886760-7522E088-2A09-4DCA-8DC0-90B732410068Q33988845-D27AFB99-7B04-4B32-AE36-0504FD06F371Q34094086-8387583A-28AD-48F7-A7D8-EEADDD54B7BFQ34201123-12AB5405-4207-4346-B821-5EC2757CA0A3Q34306449-2F89AD2F-0415-4BF7-87CE-0D3EA6F79B24Q34466930-6E05036A-60A9-4000-8B9D-7A0CD43A3319Q34505314-8DF12032-3999-404A-9BB7-21390A047F8CQ34514645-40618009-7A68-432E-8766-F9659E38CFE5Q34752142-92CEC831-6130-4F4F-B0DF-00F683FD87C5Q34918581-0CCB665E-8210-49F0-9048-283B8E9C7AEDQ35007243-1B14BD83-8030-4C1F-AC3E-2C024819017EQ35151537-48F5DDCA-7FE6-402B-AACD-44D894E84076Q35156823-BA583EFA-C903-4DE2-9D6A-C5C5A45B2668Q35745969-C62F74C2-741A-4527-ABC5-9489A7758DA5Q35879180-0F8AE595-DF6E-4C19-BCB5-85F3FEC7E012Q35931379-77C3C388-97BA-4D45-8E8E-BC65C5FA783BQ36037969-EC379E90-4E7E-4696-AC92-2335B2165F33Q36140769-D35D212D-4172-4D60-ABC9-993387FBF13EQ36254286-C90123EB-2CA1-4D95-96F2-5D9871EBA21EQ36647039-9CA1531C-806B-4215-9CDD-D951BADC9AB9Q37687548-2DE8A9BD-8442-4939-859C-C59AB36061A4Q37885158-031E9BD2-1488-43C1-818D-C848C469BBB5Q37998312-31A12518-406F-47F7-909D-6DF7C69F3A79Q38065938-4BDEA9DA-2E27-414E-AFE8-AE5D2B4F5922Q38069201-C73A0F79-9E71-439B-9AD5-40BA9D93E458Q38083549-75FFDBA8-91DF-48FB-80B6-DC7D6330ADB6Q38217975-5C11D80A-6E0D-443F-98E0-2A851B31C22EQ38502051-AD406478-ADF8-4079-82B5-C65B7D6370C8Q38954106-6ED7E733-B28D-4889-97BE-305BB0E94538Q38962140-17C8BA4F-DC88-4002-A851-2D4E8AA22A17Q39038606-6402B5A9-FBAA-4D37-BC5E-F56EE1931D2FQ39208961-6D9348DD-1443-476C-9EC3-27C007BB4466
P2860
Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dantrolene, a therapeutic agen ...... within the ryanodine receptor.
@en
Dantrolene, a therapeutic agen ...... within the ryanodine receptor.
@nl
type
label
Dantrolene, a therapeutic agen ...... within the ryanodine receptor.
@en
Dantrolene, a therapeutic agen ...... within the ryanodine receptor.
@nl
prefLabel
Dantrolene, a therapeutic agen ...... within the ryanodine receptor.
@en
Dantrolene, a therapeutic agen ...... within the ryanodine receptor.
@nl
P2093
P2860
P1476
Dantrolene, a therapeutic agen ...... within the ryanodine receptor
@en
P2093
Hiroki Tateishi
Hiroyuki Kyushiki
Hitoshi Uchinoumi
Makoto Ono
Mamoru Mochizuki
Masafumi Yano
Masunori Matsuzaki
Noriaki Ikemoto
Noritaka Koseki
Shigeki Kobayashi
P2860
P304
P356
10.1016/J.JACC.2009.01.065
P407
P577
2009-05-01T00:00:00Z